SG11201608328RA - Method for predicting response to therapy for cancer - Google Patents

Method for predicting response to therapy for cancer

Info

Publication number
SG11201608328RA
SG11201608328RA SG11201608328RA SG11201608328RA SG11201608328RA SG 11201608328R A SG11201608328R A SG 11201608328RA SG 11201608328R A SG11201608328R A SG 11201608328RA SG 11201608328R A SG11201608328R A SG 11201608328RA SG 11201608328R A SG11201608328R A SG 11201608328RA
Authority
SG
Singapore
Prior art keywords
cancer
therapy
predicting response
predicting
response
Prior art date
Application number
SG11201608328RA
Inventor
Yoon Pin Lim
Original Assignee
Univ Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Singapore filed Critical Univ Singapore
Priority to SG11201608328RA priority Critical patent/SG11201608328RA/en
Publication of SG11201608328RA publication Critical patent/SG11201608328RA/en

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/53Ligases (6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y603/00Ligases forming carbon-nitrogen bonds (6.3)
    • C12Y603/02Acid—amino-acid ligases (peptide synthases)(6.3.2)
    • C12Y603/02019Ubiquitin-protein ligase (6.3.2.19), i.e. ubiquitin-conjugating enzyme
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90Enzymes; Proenzymes
    • G01N2333/9015Ligases (6)
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
SG11201608328RA 2014-04-24 2015-04-24 Method for predicting response to therapy for cancer SG11201608328RA (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
SG11201608328RA SG11201608328RA (en) 2014-04-24 2015-04-24 Method for predicting response to therapy for cancer

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SG10201401785R 2014-04-24
PCT/SG2015/050085 WO2015163826A1 (en) 2014-04-24 2015-04-24 Method for predicting response to therapy for cancer
SG11201608328RA SG11201608328RA (en) 2014-04-24 2015-04-24 Method for predicting response to therapy for cancer

Publications (1)

Publication Number Publication Date
SG11201608328RA true SG11201608328RA (en) 2016-11-29

Family

ID=54332870

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201608328RA SG11201608328RA (en) 2014-04-24 2015-04-24 Method for predicting response to therapy for cancer

Country Status (3)

Country Link
US (1) US20170045520A1 (en)
SG (1) SG11201608328RA (en)
WO (1) WO2015163826A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180209981A1 (en) * 2015-07-23 2018-07-26 National University Of Singapore Wbp2 as a co-prognostic factor with her2 for stratification of patients for treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5976849A (en) * 1998-02-05 1999-11-02 Zeneca Limited Human E3 ubiquitin protein ligase

Also Published As

Publication number Publication date
US20170045520A1 (en) 2017-02-16
WO2015163826A1 (en) 2015-10-29

Similar Documents

Publication Publication Date Title
ZA201702382B (en) Combination therapy for cancer
IL304252A (en) Method for treating cancer
IL289947A (en) Method for treating cancer
FI3198035T3 (en) Methods for predicting drug responsiveness
SG11201605585SA (en) Targeted therapy for small cell lung cancer
GB201420859D0 (en) Tumour analysis
GB201521357D0 (en) Methods for predicting response to anti-TNF therapy
HK1231381A1 (en) Combination therapy for cancer
EP2998732C0 (en) Analysis method
IL246761A0 (en) Combination therapy for cancer
IL251141B (en) A method of predicting risk of recurrence of cancer
IL246558A0 (en) Novel methods for treating cancer
SG11201609522TA (en) Methods for treating cardiovascular diseases
PL3186332T3 (en) Method for hydraulic fracturing
GB201420832D0 (en) Location method
IL247270B (en) Method of detecting cancer
EP3164122A4 (en) Predicting response to cancer therapy
EP3121274A4 (en) METHOD FOR PREDICTING RESPONSIVENESS TO CANCER TREATMENT USING p300-INHIBITING COMPOUND
SG11201608328RA (en) Method for predicting response to therapy for cancer
PL2985126T3 (en) Method for edgebanding panels
GB201407837D0 (en) Methods of cancer therapy
GB201411567D0 (en) Quantification methods
AU2014902535A0 (en) Predicting response to cancer therapy
GB201507268D0 (en) Method for stimulating aerogenosis
GB201411884D0 (en) Cancer therapy